Journal article
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Abstract
BACKGROUND: Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity.
METHODS: In parallel, randomised, double-blind, controlled, clinical trials we compared candesartan with placebo in three distinct populations. We studied patients with left-ventricular ejection fraction …
Authors
Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Östergren J; Yusuf S; Investigators and Committees FTC
Journal
The Lancet, Vol. 362, No. 9386, pp. 759–766
Publisher
Elsevier
Publication Date
9 2003
DOI
10.1016/s0140-6736(03)14282-1
ISSN
0140-6736